Replication-defective viruses as vaccines and vaccine vectors (Q34477918)

2 August 2017

1 reference

title

Replication-defective viruses as vaccines and vaccine vectors (English)

1 reference

2 August 2017

0 references

1 reference

Tim Dudek

1

1 reference

PubMed ID

16364753

2 August 2017

David M Knipe

series ordinal

2

1 reference

PubMed ID

16364753

2 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

2 August 2017

10

1 reference

inferred from page(s)

published in

Virology

1 reference

2 August 2017

344

1 reference

2 August 2017

230-239

1 reference

2 August 2017

1

1 reference

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Humoral response to herpes simplex virus is complement-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Herpes simplex virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recent progress in herpes simplex virus immunobiology and vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Adenovirus and adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Alphavirus vectors and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Toll‐Like Receptor and Cytokine Expression Patterns of CD56+T Cells Are Similar to Natural Killer Cells in Response to Infection with Venezuelan Equine Encephalitis Virus Replicons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Alphavirus vectors for gene expression and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Human monkeypox infection: a family cluster in the midwestern United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Development of a preventive vaccine for Ebola virus infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Recombinant fowlpox virus inducing protective immunity in non-avian species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Efficacy studies on a canarypox-rabies recombinant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Myeloid C3 Determines Induction of Humoral Responses to Peripheral Herpes Simplex Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

7 January 2021

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

7 January 2021

Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

7 January 2021

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

7 January 2021

Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.020

7 January 2021

10.1016/J.VIROL.2005.09.020

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

16364753